OPANA ER is a sustained release formulation of oxymorphone which uses our patented TIMERx technology. It is indicated for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.
Endo Pharmaceuticals has successfully launched this product in the US, rapidly exceeding $100 million in sales.
Penwest and Endo are seeking partners outside of North America and outside of Europe with established commercial capabilities to leverage our success in the US.
The formulation is covered by multiple patents, and is commercialized in the US.
The product is available for licensing outside the US.
Carlos Velez
Director, Business Development and Licen
Penwest is a specialty pharmaceutical company dedicated to bringing to the marketplace innovative products that help improve the lives of patients.
View profile© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd 
All rights reserved. Terms and Conditions | Contact us
